Dually Efficacious Medicine Against Fibrosis and Cancer
Author:
Open Access
- 4 March 2019
- journal article
- review article
- Published by MDPI AG in Medical Sciences
- Vol. 7 (3) , 41
Abstract
Although there is a contemporary consensus of managing a severe disease with multi-targeted approach-based therapeutic combinations, it should not be ignored that certain patho-biological pathways are shared by distinct medical conditions and can be exploited to develop an exceptional type of medication conferring a dual efficacy. This article thus presents a spectrum of emerging molecular targets that substantially contribute to the pathogenesis of both fibrotic and neoplastic disorders, including kinase activities, cytokine cascades, and protein dynamics among others. Moreover, recently approved therapeutic agents in this regard have been sorted out to corroborate the drug’s ability upon targeting each one of these molecular pathways to treat fibrosis and cancer simultaneously. It not only streamlines an overlapping mechanistic profile in the pathogenesis across these two medical conditions, but also inspires clinicians and pharmaceutical innovation to tackle concomitant diseases, such as fibrosis and cancer, with an optimally efficacious medication.Keywords
This publication has 63 references indexed in Scilit:
- Stem cell signaling as a target for novel drug discovery: recent progress in the WNT and Hedgehog pathwaysActa Pharmacologica Sinica, 2013
- Role of the Microenvironment in the Pathogenesis and Treatment of Hepatocellular CarcinomaGastroenterology, 2013
- LY2109761 Attenuates Radiation-Induced Pulmonary Murine Fibrosis via Reversal of TGF-β and BMP-Associated Proinflammatory and Proangiogenic SignalsClinical Cancer Research, 2012
- Bortezomib a safety treatment for patients with Multiple Myeloma and Cystic FibrosisMediterranean Journal of Hematology and Infectious Diseases, 2012
- Reversible Decrease of Portal Venous Flow in Cirrhotic Patients: A Positive Side Effect of SorafenibPLOS ONE, 2011
- Cooperative interaction of CTGF and TGF-β in animal models of fibrotic diseaseFibrogenesis & Tissue Repair, 2011
- Renin–angiotensin–aldosterone system blockade for cardiovascular diseases: current statusBritish Journal of Pharmacology, 2010
- Proteasomal Regulation of Pulmonary FibrosisProceedings of the American Thoracic Society, 2010
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Thalidomide reduces tumour necrosis factor α and interleukin 12 production in patients with chronic active Crohn's diseaseGut, 2002